Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus ULTRATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus ULTRATAG.
FLUORINE F-18 vs ULTRATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
Inhibits hepatic glucose production by activating AMP-activated protein kinase (AMPK) and reduces intestinal glucose absorption; also improves insulin sensitivity.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
NOT FOUND
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Terminal elimination half-life is 12-15 hours (mean 13.5 h); clinically significant for twice-daily dosing in hepatic impairment or drug interactions.
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Primarily renal excretion of unchanged drug (60-70%); biliary excretion accounts for 20-25%; fecal elimination <10%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical